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Abstract
Introduction: A substantial number of therapeutic drugs for Alzheimer’s disease (AD) have failed in late-stage trials,
highlighting the translational disconnect with pathology-based animal models.
Methods: To bridge the gap between preclinical animal models and clinical outcomes, we implemented a
conductance-based computational model of cortical circuitry to simulate working memory as a measure for
cognitive function. The model was initially calibrated using preclinical data on receptor pharmacology of
catecholamine and cholinergic neurotransmitters. The pathology of AD was subsequently implemented as synaptic
and neuronal loss and a decrease in cholinergic tone. The model was further calibrated with clinical Alzheimer’s
Disease Assessment Scale-cognitive subscale (ADAS-Cog) results on acetylcholinesterase inhibitors and 5-HT6
antagonists to improve the model’s prediction of clinical outcomes.
Results: As an independent validation, we reproduced clinical data for apolipoprotein E (APOE) genotypes
showing that the ApoE4 genotype reduces the network performance much more in mild cognitive impairment
conditions than at later stages of AD pathology. We then demonstrated the differential effect of memantine, an
N-Methyl-D-aspartic acid (NMDA) subunit selective weak inhibitor, in early and late AD pathology, and show that
inhibition of the NMDA receptor NR2C/NR2D subunits located on inhibitory interneurons compensates for the
greater excitatory decline observed with pathology.
Conclusions: This quantitative systems pharmacology approach is shown to be complementary to traditional
animal models, with the potential to assess potential off-target effects, the consequences of pharmacologically
active human metabolites, the effect of comedications, and the impact of a small number of well described
genotypes.
Introduction
As diseases progress, different treatment strategies may be
necessary to compensate for changing bio-logical condi-
tions. Therefore, we need to estimate how and when such
changes take place so that the treatment may be altered in
pace as the disease progresses. However, unless specific
biomarkers are available to directly measure progression
of the disease, we must rely on indirect functional indica-
tors to signal the progress. For complex diseases such as
Alzheimer’s disease (AD), biophysical modeling can pro-
vide an important tool [1] to link indirect functional
indicators with the underlying biological process and pre-
dict both the timing and mechanisms that indicate effec-
tive treatments at various stages of the disease.
Many experimental therapeutics in AD are based on dis-
ease-modifying strategies, yet the ultimate clinical test is
functional. Although cognitive outcome is dependent upon
integrity of the underlying neuronal structures, cognition is
modulated by the interaction of many neuromodulatory
systems that have been primary targets of medications.
The only approved medications for AD are based on the
cholinergic system [2], and specific muscarinic [3] and
nicotinic targets [4] are currently under investigation.
Other symptomatic interventions under investigation
include serotonergic targets, such as 5-HT4[5] and a 5-HT6
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[6,7]. However, these treatments are most effective during
the middle stages of the disease, after mild cognitive
impairment (MCI) develops into AD, and before the late
stages.
In order to provide better guidance on clinical candi-
date development, we have developed a conductance-
based, biophysical model of cortical networks to simulate
the progression of AD. The model represents disease
pathologies as neuronal and synaptic loss and changes in
cholinergic tone. Neuromodulatory effects are included
by calculating receptor activations in the presence of nor-
mal and pathological levels of modulators and drugs, and
then coupling receptor activation to biophysical changes
in the network. To link these pathologies to cognitive
function, we simulate a working memory task and
calibrate the outcome with clinical data (Figure 1).
The calculated measure of working memory is modi-
fied by pathology such as synaptic loss and by changes in
the receptor activations. This output of the model, the
working memory span, is used to calibrate the receptor
parameters with a clinical database. The calibrated model
represents the underlying state of the cortex during each
stage of the disease, and predicts the systems level
changes caused by interventions that lead to changes in
functional symptoms. Predictions using the calibrated
model include the transition from MCI to AD, and the
progression of pathology in synaptic and neuronal loss
throughout the disease.
We also demonstrate the mechanism of action of mem-
antine, an N-Methyl-D-aspartic acid (NMDA) receptor
inhibitor, on late stage AD. We show that the loss of
excitatory neurons in late stage AD shifts the excitatory-
inhibitory balance in cortical circuitry so that memantine
improves cognitive function. Memantine is currently
approved for the treatment of moderate-to-severe AD
and has shown clinical benefit in these patients [8], but
the mechanism of action has not previously been clearly
demonstrated.
These results suggest that computational-based mod-
eling [9] could become a critical tool for improving
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Figure 1 Overview of modeling platform. The modeling platform consists of two components, a receptor competition model (left column)
and a biophysical neuronal network model (center column). The receptor competition model calculates the activation of receptors for
neuromodulators (M1, a7, a4b2 receptors for acetylcholine; D1, D4 receptors for dopamine; 5-HT1A, 5-HT2A, 5-HT3 receptors for serotonin; a2A
receptors for norepinephrine) for the region of the brain represented by the neuronal network model. The receptor activations are used to
adjust modulate synaptic and membrane currents in the network model. The output of the network model simulates a burst of pyramidal cell
activity as a measure of working memory (right column). The platform is initially calibrated to generate an average working memory span of
over 9 sec (top row), and a disease pathology such as loss of neurons and synapses reduces the working memory span (middle row). Changes
in the receptor activations, such as increased cholinergic tone change the working memory span (bottom row) to reduce the symptoms.
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Methods
The computational model has two main components, a
receptor competition model [10] and a conductance-based
cortical model [11] as shown in Figure 1. The receptor
competition model is used to calculate the activation of
modulator receptors that influence the neurons and synap-
tic conductances in the cortical model. The cortical model
simulates the activity of cortical pyramidal cells and inhibi-
tory interneurons to estimate the burst firing duration
associated with a working memory task. The spiking activ-
ity of the cortical model is compared with clinical data to
calibrate the model and analyze the progression of AD and
mechanisms of action for symptomatic treatments.
The receptor competition model
We implemented a receptor competition model to simu-
late the competition between neurotransmitter, drug, its
metabolite and a possible radiotracer [10]. We use this
model to calculate the postsynaptic serotonergic and cho-
linergic receptor activation for different clinical conditions
because 5-HT6 antagonists have been tested in different
doses and acetylcholinesterase inhibitors (AChE-I)
increase free ACh at different doses. This receptor compe-
tition model is a set of ordinary differential equations that
describes the time-dependent changes in pre- and postsy-
naptic receptor activations, neurotransmitter and drug
levels in the synaptic cleft and amount of binding to differ-
ent receptors.
If [NT] is the free neurotransmitter (for instance 5-HT)
concentration and [Rf] is the concentration of free recep-
tors, then the change in receptors bound by neurotransmit-




= kion · [NT] · [Rf ] − kion · Kid · [Ri] (1)
where the super(sub)script i has four possible values
(n = neurotransmitter, d = drug, m = metabolite and t =
tracer). Combined with the continuity equation, Rf = Ro−
Rn− Rd− Rm− Rt, the system of differential equations is
solved numerically to obtain the activation (Ro = concen-
tration of receptors). The initial condition that all recep-
tors begin in the free state (subscript n refers to the





ential equations are integrated with a fourth-order Runge-
Kutta algorithm with a time step of 0.01 msec using
proprietary custom software written in Java.
The amount of free neurotransmitter depends on two
processes, exponential decay and quantal release. Expo-
nential decay is classically defined as [NT] (t) = [NT(0)]
exp(−t ln(2)/τ1/2) where τ1/2 is the half-life of the decay
process. The amount of presynaptic receptor activation
which occurred 150 ms before the current release event











where r0 is the base release amount, rmaxis the maxi-
mum relative change for release, A is the receptor activa-
tion at the specified time in the past, S is the sensitivity to
presynaptic receptor and B0 is the amount of normal pre-
synaptic binding that one would expect in the tonic case.
All differential equations are solved with a fourth-order
Runge-Kutta method with a time step of 0.01 msec.
In addition, the release can be modulated by a depres-
sion or facilitation mechanism [13]. Instead of using inter-
nal Ca++ levels to determine neurotransmitter release, we
consider the facilitation and depression based solely on
the amount of time elapsed since the previous firing using
a phenomenological equation. If we denote the time of the
nth firing by tn, then the release amount is modified based







[−kf (tn − ti)]− wd exp[−kd(tn − ti)]
)
(3)
where wfis the facilitation weight, wdis the depression
weight, kfis the decay rate of facilitation and kdis the decay
rate of depression. The simulation is initiated by first find-
ing the equilibrium given a constant amount of free neu-
rotransmitter at 500 nM and then goes on for a transitory
time of 5 seconds at the predetermined tonic firing rate.
Finally, the simulation runs for an additional 10 seconds
during which time average binding levels are determined.
While konand koffparameters are determined experimen-
tally, all the parameters that describe the presynaptic neu-
rotransmitter physiology are calibrated with preclinical
experiments using rapid-cyclic fast voltammetry on levels
of neurotransmitters.
Using the competition model between neurotransmit-
ter, drug and tracer for binding at the postsynaptic
receptor, we determined the drug concentration that
corresponds to a clinically measured radiotracer displa-
cement. This value for the drug concentration is the
free and functional intra-synaptic concentration that is
dependent upon the pharmacokinetic properties of the
drug and was used in further calculations.
The Cholinergic synapse model. As the mainstay of
Alzheimer therapy are cholinomimetic drugs such as
Acetylcholinesterase inhibitor (AChE-I), it is necessary
to have a well calibrated computer model of the choli-
nergic synapse [14]. Briefly, the presynaptic autoregula-
tion of cholinergic neurotransmission is regulated by M2
muscarinic receptor (mACh-R) [15], the physiology of
which has been studied using M2 receptor knockout
mice [16]. Results on the pharmacological effects of
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oxotremorine and muscarine on quantal ACh release in
wild-type and M2 receptor knockout provide biological
data for which the negative autoreceptor coupling para-
meters were calibrated. Presynaptic release of endogen-
ous ACh is further synchronized with firing frequencies
of the cholinergic nerve endings, which are typically in
the 6-8 Hz range [17,18].
Removal of ACh from the cholinergic cleft is mediated
by the activity of the acetylcholinesterase enzyme, one of
the fastest enzymes in the human body. The pEC50 for
ACh hydrolysis by AChE is -6.6 with a hill slope of 0.9,
while the enzyme saturates at a maximal turnover rate of
25,000/sec [19]. The density of AChE molecules is 2400/
sq-micron [20] for the neuromuscular junction. This con-
strains the values for the half-life of the free ACh.
The amount of ACh released per action potential is in
the range of 7,000 to 10,000 molecules as measured by
fluctuation analysis [21], although more recent data in frog
muscle acetylcholine receptors suggest single quanta of 70
molecules and the release of 5-6 quanta per action poten-
tial [22]. The volume of a cholinergic synapse can be esti-
mated from EM studies; for instance the cholinergic
synapse in the ventral tegmental area (VTA) can cover an
area of 1 μm2[23]. Assuming a distance between pre-and
postsynaptic membrane ranging between 0.05 and 0.2 μm,
our estimate for the volume of a cholinergic synapse
ranges from 5-20×10-17 l. A concentration of 1uM corre-
sponds to 30 to 120 molecules in the synaptic cleft. This
number serves as the basis for the amount of ACh released
per action potential and further calibration of the choliner-
gic synapse [14].
The cortical network model
We extended a biophysically realistic model of a net-
work comprised of four-compartment pyramidal cells
and two-compartment gamma-Aminobutyric acid
(GABA) interneurons [11,24] with the receptor physiol-
ogy of 18 different dopaminergic, serotonergic, noradre-
nergic, and cholinergic receptors. We describe here only
a brief overview of the models to emphasize the changes
relative to the published article [11].
For more precise implementation of the Alzheimer’s
pathology, we extended the network to a system of 80
pyramidal cells and 40 interneurons and we modified
the connectivity strength so that it had similar firing fre-
quencies for the different types of neurons as the 30
neuron network [11].
We added the receptor physiology of 18 different dopa-
minergic, serotonergic, noradrenergic, and cholinergic
receptors to the NMDA, a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid ApoE4 (AMPA) and GABA-A
receptors already present in the published source [11].
The circuit connectivity is based on estimations from the
relative number of pyramidal cells and interneurons [24]
that synapse onto each other. In our implementation 40%
of the interneurons do not synapse with pyramidal cells,
but form a small recurrent network between themselves
and other inhibitory interneruons. This network has some
50,000 synapses. Basically, the network is initially cali-
brated using single-cell recordings in primates [11,25].
The receptor couplings are based on documented
intracellular processes with these receptors and are cali-
brated using the correlation between the effect of thera-
peutic interventions in the network and their clinical
working memory performance on the N-Back test in
both normal subjects and schizophrenia patients.
An mGluR5-dependent delayed after-depolarization
current was added to the model to increase the spiking
rate of pyramidal cells for several seconds and was
implemented as an a-function in the model with a time
constant similar to the observation in [26]. In contrast
to the network in [11], 40% of the interneurons do not
synapse with pyramidal cells but synapse with other
inhibitory interneurons that connect to pyramidal cells
to be consistent with the relative number of pyramidal
cells and interneurons [24].
Figure 2 shows the general architecture of the cortical
network. Each pyramidal cell consists of a distal den-
drite, a proximal dendrite, a cell soma and an apical
dendrite, whereas an interneuron has only a cell soma
and a dendritic compartment. While all pyramidal cells
synapse with themselves to form a recurrent network
and all of them make synapses with interneurons, only
60% of the interneurons synapse with pyramidal cells;
the remaining 40% form an internal recurrent network.
There is a constant background synaptic noise [11] that
simulates the effect of the neurons that are not repre-
sented explicitly in the model. A few receptors that
modulate the glutamatergic and GABA-ergic connec-
tions are also shown in Figure 2. Modulation of the con-
nections is implemented by scaling the maximum
conductance of the synaptic connection proportionally
to the activation of each receptor. Excitatory AMPA and
NMDA synapses onto pyramidal cells are modulated by
D1R with a factor of (1 + PsynD1 · AD1), where AD1 is the
relative difference of D1R activation in the presence of
the drug compared with the control D1R activation and
PsynD1 is the coupling parameter that is calibrated using
clinical data. In addition, excitatory synapses onto pyra-
midal cells are modulated by M2 receptors via an a7
mechanism that is implemented similarly. Excitatory
synapses onto inhibitory interneurons are modulated
similarly except that AMPA receptors are modulated by
an additional factor due to D4R activation.
Inhibitory GABA-A synapses are also modulated by
D1R as with excitatory neurons, but have independent
coupling parameters. In addition, GABA-A synapses are
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modulated by M2 receptors via an a4b2 mechanism
implemented similarly as for excitatory synapses. Inhibi-
tory GABA-A synapses onto inhibitory interneurons are
further modulated by 5-HT3 receptors.
Changes in membrane potential were calculated using
partial differential equations that were integrated using
the simulation package NEURON [27]. The time course
of the membrane potential, V, was determined by inte-




(V) = IKdr + IKCa + . . . . (4)
where C is the membrane capacitance and Ia = ga(V −
Ea) is a term in the sum of membrane currents described
in detail in [11]. The currents are calculated by the vol-
tage-dependent ionic conductance gaof an a-type ion
channel, and Eais the reversal potential of an a-type ion
channel.
Figure 2 Schematic diagram of the connectivity and receptors in the prefrontal cortex network. Schematic diagram of the connectivity
and receptors in the prefrontal cortex network. The position of different types of cholinergic (M1, a7, a4b2), dopaminergic (D1, D4), serotonergic
(5-HT1A, 5-HT2A, 5-HT3), noadrenergic (a2A), glutamate and GABA receptors is shown according to their preclinical data. The memory stimulus (M)
is given at 2 sec into the simulation and represents a sensory or conceptual stimulus that is introduced into the network. The background noise
(B) represents the interaction of this particular network with the rest of the cortex and the brain and is described as a Poisson process and is
present throughout the simulation.
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The voltage-sensitive ionic conductances were calculated
using activation (xa) and inactivation (ya) variables:








(x∞a − xa), (5)
where g¯a is the maximum ionic conductance, and nais
the power of the activation variable. The asymptote (x∞a )
and decay (τxa) constants are functionally related to the
first-order rate constants in the Hodgkin-Huxley formula-
tion [28]. The gating variables are themselves dependent
on the membrane potential, V, through empirically derived
relationships for each channel type so that x∞a and τxa are
defined by voltage-dependent gating variables, a(V) and
b(V). The inactivation variables obey a similar first-order
equation (see Table 1 for parameters and Table 2 for
gating functions used in this model).
To model the response of excitatory synaptic inputs,
we implemented an excitatory chemical synaptic input as
in published models of AMPA and NMDA synapses [29].
When a presynaptic spike occurred at time tpre, a time
dependent conductance was initiated that was based on a
two state kinetic scheme [30] described by rise time con-
stant (τrise), and decay time constant (τdecay). The maxi-
mal inward depolarizing conductance (g¯) was calibrated
to generate physiological network behavior, and the
reversal potential for these conductances, Vglu = 0 mV
[30]. The following equation describes the AMPA synap-
tic conductance (gglu) of both AMPA and NMDA recep-
tors used in this model:
gglu(t − tpre) = g¯(e−(t−tpre)/τdecay − e−(t−tpoe)/τrise) (6)
The synaptic current for each excitatory synaptic release
was then calculated as, Iglu = gglu(V − Vglu). The Mg
2+ block
for NMDAR is based on physiological concentrations of
Mg2+ by multiplying the current, Iglu, by a voltage-depen-
dent factor [30,31]. Inhibitory chemical synapses represent
GABA-A receptors and are also implemented as a two
state kinetic scheme [30] similar to the AMPA receptors.
We use the GABA-A (chloride) reversal potential appropri-
ate for the cell types.
In addition to the synaptic channels, AMPA and
NMDA from glutamatergic neurons and GABA-A from
interneurons, there are membrane ion-channels in all com-
partments. Every cellular compartment of both pyramidal
cells and interneurons has a delayed rectifying K+ (Kdr)
channel, a fast Na+ (Naf) channel and a leak channel. Pyra-
midal compartments also have a slowly inactivating K+
(Ks) channel, a Ca2+ mediated K+(KCa) channel, a persis-
tent Na+ (Nap) channel (only in some compartments) and
a high-threshold L-type Ca2+ (Hva) channel.
A stimulus is initiated by injecting a brief current at t =
2000 msec which starts the firing of the target pyramidal
cells. Without further stimuli, this synchronized firing pat-
tern goes on before it gets degraded by the background
noise and the interference of the distractor neurons. This
time span, called the working memory span, is usually in
the range of 4-10 sec and corresponds to the time a cer-
tain pattern is held in working memory (for a review
see [32]).
This time span, called working memory span, is defined
as the time a synchronous firing in the neurons that are
stimulated is sustained without further stimulation. We
first divide the time axis in bins of 200 msec and count
the number of neurons firing in that time window and
determine the time points where this number exceeds
M/2, where M is the number of neurons stimulated at t
= 2 sec (M = 40). The time difference between these two
transition points is the memory span (Figure 3).
Implementation of receptor pharmacology
This subsection describes specifically the implementation
of 5-HT and ACh neurotransmission physiology. Other
neuromodulatory processes (dopaminergic (DA), noradre-
nergic (NE)) are implemented using similar approaches. In
general, we assume a linear normalized relationship
between receptor activation and biological effect on phy-
siological responses such asXeffY = (X
A
Y − XCY )/XCY , where
XAY and X
C
Y are the actual activation levels of receptor X
subtype Y (for instance 5-HT6) after treatment (A) and the
untreated (healthy) control levels (C).
5-HT6 receptor antagonism increases cortical ACh, DA
and NE but not 5-HT with a maximal time-dependent
effect of +200-250%; while the area under the curve is
maximally increased tenfold [33]. 5-HT6 receptors are
predominantly located in subcortical areas [34] and
Table 1 Compartment parameters.
Compartment Length, μm Diameter, μm gNaf gNap gHva gKdr gKs gCa
Pyr - Apical-distal 400.0 2.6 0.028 0 0.000255 0.0092 0.00018 0.0022
Pyr- Proximal-distal 400.0 2.6 0.028 0.001 0.00063 0.0092 0.00018 0.0038
Pyr - Basal 150.0 16.0 0.028 0.001 0.00063 0.0092 0.00018 0.0038
Pyr - Soma 86.3 6.14 0.086 0.0022 0.000306 0.0338 0.000105 0.0022
Int - Dendrite 150.0 10.0 0.02 - - 0.008 - -
Int - Soma 15.0 15.0 0.1 - - 0.04 - -
Parameters adapted from [11] for dimensions and current densities of the model compartments.
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antagonism directly increases K+ mediated ACh release
in cortical and hippocampal slice [35].
With regard to subcortical DA activity; acute 5-HT6
receptor antagonism shifts DA firing in VTA from
bursts to tonic firing with a maximum decrease of 35%
in burst firing, while spontaneous activity of substantia
nigra DA neurons increases by 40% after chronic 5-HT6
receptor antagonism [36].
Table 2 Compartment parameters.
Current m a b x∞ τx (ms)
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Gating functions [11] used for the membrane currents in the model neurons. The cell type and current are listed at the left, and the column head ins refer to Eq
5: gating exponent (m), gating variables (a and b), the equilibrium activation(inactivation) (x∞), and the activation(inactivation) time constant (τx).
Figure 3 Raster plot of the working memory model output. A raster plot of the working memory model output (left panel) illustrates the
concept of working memory span. Each line of asterisks is the activity of a single neuron with each asterisks indicating an action potential
occurred at that time for the neuron. For simplicity we only show 10 excited pyramidal neurons, 10 unstimulated pyramidal cells and 10 GABA
interneurons. At time 2 sec, a current (equivalent to a ‘memory’ stimulus) is injected into the attractor neurons (lowest ten lines) and these
neurons then fire a sustained burst for a certain period until the stochastic noise starts to deteriorate the attractor pattern. The memory span is
the time in seconds over which at least 80% of the attractor neurons fire within a similar time period (right panel).
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We implemented the effect of 5-HT6 receptors in the
cortical working memory model as an increase in free DA,
NE and ACh that impacts activation levels of D1, D2, D4,
M1, M2, a7 nicotinic ACh receptor (nACh-R), a4b2 nACh-
R and a2A receptors. Let P5HT6 be a freely adjustable cou-
pling parameter that will be fitted using clinical data.
Given the actual, 5HT6A, and control, 5HT6C, activation
levels of the 5-HT6 receptor, we calculate the effect on
DA, NE and ACh receptors as,




where x = 1,2, or 4 (dopaminergic receptors),




where x = 1,2 (muscarinic receptors), and




where x = a7 or a4b2 (nicotinic receptors).
Cholinergic physiology is implemented through the M1
receptor and both the a7 and the a4b2 nACh-R synapses,
although pharmacology at the M2 receptor can play a role
at this presynaptic autoreceptor. Their interactions are
simulated using the cholinergic (muscarinic) receptor
competition model. This interaction is important as many
AD patients are on cholinomimetics such as acetylcholi-
nesterase inhibitors.
Experimental data on pyramidal cells with ACh and spe-
cific M2 antagonists suggest that modulation of both M1
receptor and M2 receptor leads to a receptor activation-
dependent average membrane potential change (Gulledge
and Stuart, 2005, Gulledge et al., 2009), experimentally
fitted with the following formula ΔM(mV) = −4 +6AM1 +2
(1−AM2), where AM1 and AM2 are normalized M1 and M2
activation (both are bound between 0 and 1). This resting
membrane potential change is caused by a change in K+
channel conductance as g’Kdr = gKdr(1 + ΔM · PM1), where
PM1 is an adjustable parameter determined from clinical
calibrations.
We implement the effect of a7 nACh-R modulation
through presynaptic glutamate (Glu) release on Glu
synapses that connect to pyramidal cells and interneurons
through the following formula




where x is either NMDA or AMPA.
Similarly a4b2 nACh-R regulates the GABA release at
presynaptic afferent GABA neurons synapsing onto both
interneurons and pyramidal cells with a coupling para-
meter Pα4β2.
The parameters coupling the documented intracellular
processes with these receptors are further calibrated
using the correlation between the effect of therapeutic
interventions in the network and their clinical working
memory performance on the Alzheimer’s Disease
Assessment Scalecognitive subscale (ADAS-Cog) scale
in Alzheimer’s patients (as listed in Table 3).
There was no attempt to synchronize the activity of neu-
romodulatory pathways, such as dopamine and serotonin
on the dynamics of the cortical network, because there are
not enough data available. Many of these pathways fire
tonically at low frequencies (1-5 Hz range), although short
bursts might be present [37]. Since we are interested in
somewhat longer-term properties (that is the capacity of
sustained network activity over many seconds), we antici-
pate time-dependent changes in neuromodulatory path-
ways to have a limited impact. In addition, the
pharmacodynamic half-life of drugs that change receptor
activation levels is much longer than the tens of seconds
the network activity is sustained. For instance the half-life
of donepezil is well over 48 hr [38]. Therefore as a first
approximation, the neuromodulatory effect is averaged
over the full time range of the simulation.
Introducing pathology in the model
We implement AD pathology as a loss of cortical neu-
rons [39] at a rate, τN(%/week) and synapses from pyra-
midal neurons [40] with a rate τS(%/week). Both
excitatory-excitatory (e-e) and excitatory-inhibitory (e-i)
synaptic connections are eliminated at the same rate, but
because there is an additional pyramidal cell loss, e-e
synapses tend to decrease faster. We constrain the distri-
bution of neuronal loss so that the number of stimulated
and unstimulated pyramidal cells must be the same.
Reduced cholinergic tone [41] is implemented as a free
parameter on all cholinergic receptors (M1 and M2 mus-
carinic receptors, and a7 and a4b2 nicotinic receptors).
In addition we introduced a placebo effect at week 12
using an increase in general cortical dopaminergic tone
[42].
For the calibration of the Alzheimer disease network,
we collected the publicly available data of either sex from
clinical trials in mild-to-moderate AD patients using
ADAS-Cog clinical scales (Table 3). The clinical effects
of AChE-Is were studied in a population-kinetic model
using a meta-analysis of all approved AChE-Is [43].
Using the parameters reported in [43], Table 2, we calcu-
lated the clinical responses of the placebo and AChE-Is.
In addition we also included reported clinical data on
5-HT6 antagonists [7] and placebo data at 78 weeks from
tarenflurbil and tramiprosate trials [44-46]. Altogether we
used 28 different clinical interventions over four time
points (12, 26, 52 and 78 weeks), four drugs (donepezil,
galantamine, rivastigmine and SB742457) with up to three
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doses. ApoE4 effects were introduced using specific
synapse loss [47] and cholinergic deficit [48].
The calibration of the network was performed using
design of experiment (DOE) statistical techniques, rather
than one factor at a time (OFAT), because OFAT techni-
ques are computationally intensive and are unable to
detect interaction between parameters to be calibrated
[49]. A good robust approach uses 2n simulations, where
n is the number of free parameters, compared to 2n for a
full OFAT design [50]. DOE techniques are computation-
ally effective and provide a sound statistical approach to
identify the driving parameters. Basically, this approach
progresses in two parts. First a factorial approach identifies
the major drivers of the optimization process and limits
broadly the range of individual parameter settings, allow-
ing fast optimization in a multi-dimensional parameter
space. Second, a surface response analysis can be used to
probe the (much smaller) parameter space in order to find
the optimum.
Calibration of serotonergic synapse
Because 5-HT6 antagonism is extensively used in the cali-
bration of the network, we first calibrate the human sero-
tonergic synapse model, using a combination of in vivo
experimental data on free 5-HT levels in preclinical animal
models and human imaging data with specific radiotracers
(Figure 4A).
We use fast cyclic voltammetry data in mouse slices [51]
which have been shown to be rich in serotonergic innerva-
tion. Free 5-HT levels are measured after forced firing,
providing experimental data for calibrating the presynaptic
physiology. The 5-HT1B receptor is the most important
autoreceptor for most projection serotonergic neurons,
while 5-HT1A is the major autoreceptor regulating dorsal
raphe firing [52]. Binding of 5-HT to the 5-HT1B receptor
was described by affinity Kivalues of 23.4 nM for the
antagonist tracer displacement and 4.2 nM for the agonist
tracer while EC50 value was 8.5 nM [53]. We then
adjusted the parameters of the presynaptic physiology
until we obtained the best correlation between model out-
comes and experimental values, and repeated this for dif-
ferent ratios of intra-synaptic over extra-synaptic free
5-HT.
We fitted the five parameters of the presynaptic physiol-
ogy (relative sensitivity, facilitation weight, facilitation half-
life, depression weight, depression half-life) to the 10
experimental results on the forced firing frequency (Figure
4B-C). A coarse parameter search was followed by the
method of steepest descent to minimize the square value
of the differences between experimental and model results.
This resulted in the values of 7.75 for RelSens, 1.1 and 0.42
for facilitation and depression weight respectively and 90
and 120 msec for facilitation and depression half-life
respectively.
An important issue is how much of the intrasynaptic
5-HT is detected by fast cyclic voltammetry probes.
Modeling studies of the glutamate synapse [54] suggest
that intrasynaptic levels can be between one and twenty
times the measured extrasynaptic levels.
Because it is important to know the free 5-HT level in
the human situation, the strategy is to systematically vary
the ratio of extra- versus intrasynaptic free 5-HT, for each
of these ratios, calibrate the ‘mouse’ 5-HT synapse, and
then select the best ratio that has the highest correlation
between the output of the synaptic model and actual clini-
cal data on human serotonin imaging experiments. For
Table 3 Clinical Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) used in the calibration.
Drug Dose Time (weeks) ADAS-Cog Effect Drug Dose Time (weeks) ADAS-Cog Effect
Placebo 0 12 0.27 Galantamine 16 26 -1.10
Placebo 0 26 1.87 Galantamine 16 52 1.49
Placebo 0 52 5.07 Galantamine 24 12 -1.96
Placebo 0 78 7.10 Galantamine 24 26 -1.10
Donepezil 5 12 -1.77 Galantamine 24 52 1.49
Donepezil 5 26 -0.27 Rivastigmine 6 12 -0.66
Donepezil 5 52 2.87 Rivastigmine 6 26 0.70
Donepezil 10 12 -2.12 Rivastigmine 6 52 3.71
Donepezil 10 26 -0.64 Rivastigmine 12 12 -1.82
Donepezil 10 52 2.48 Rivastigmine 12 26 -0.77
Galantamine 8 12 -1.77 Rivastigmine 12 52 2.01
Galantamine 8 26 -0.95 SB-742457 5 26 -0.22
Galantamine 8 52 1.29 SB-742457 15 26 -0.66
Galantamine 16 12 -1.96 SB-742457 35 26 -1.12
Clinical ADAS-Cog changes for different drugs, doses and time points, used in the calibration of the AD network model. The values are derived from the
population kinetic model based upon a meta-analysis and other reports on placebo and 5-HT6 antagonists.
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this we simulated positron emission tomography (PET)
radiotracer displacement human imaging studies using
5-HT receptor-specific radiotracers. We then selected the
ratio between intra- and extrasynaptic free 5-HT that best
fits the displacement of 5-HT2A receptor tracers in humans
treated with certain serotonergic modulators with affinity
for the 5-HT2A receptor, more specifically schizophrenia
patients treated with antipsychotics.
We simulated the following clinical imaging experiments:
treatment with 30 mg aripiprazole resulted in a 58% displa-
cement of setoperone at the 5-HT2A receptor and over 90%
displacement of raclopride at the D2 receptor [55]. Given
the binding values for aripiprazole of 3.3 nM for D2 recep-
tor, we can then calculate the functional free concentration
of the drug at the striatal D2 receptor in that clinical situa-
tion, which allows us then to simulate the displacement of
setoperone with aripiprazole (affinity 21.8 nM for 5-HT2A
receptor), assuming the free concentration of aripiprazole
is the same in the cortex as in the striatum.
For the other imaging studies at the 5-HT2A receptor, no
displacement at the D2 receptor was described in the
reported studies. We therefore determined the functional
brain concentration of the antipsychotics for that particular
clinical dose using the D2 receptor specific raclopride tra-
cer imaging experiments reported for similar clinical doses
in other patient groups in a primatized model of the striatal
synapse [10]. Because raclopride displacement is measured
functionally, it takes into account many confounding issues
Figure 4 Serotonin synapse modelling. (A) Processes involved in measuring free serotonin levels by fast cyclic voltammetry. In this particular
simulation only the change in free 5-HT, but no postsynaptic activation level is measured. The simulation setup forces high frequency firing on
the presynaptic nerve endings and allows calibration of the different presynaptic parameters that regulate the coupling between presynaptic
autoreceptor activation, firing history and subsequent neurotransmitter release. Some parameters, such as 5-HT release and half-life are
constrained by biological limits. (B) Correspondence between model outcomes and experimentally reported values in the mouse substantia
nigra under forced firing frequencies. The model parameters of the serotonergic synapse are adjusted to show a good correlation with the
experimental data. This particular calibration is for the situation where the extrasynaptic concentration equals the intrasynaptic free level of 5-HT.
(C) Correspondence between model outcomes and experimentally reported values [51] in the mouse dorsal raphe under forced firing
frequencies where a specified number of pulses was given at 30 Hz. The model parameters of the serotonergic synapse are adjusted to show a
good correlation with the experimental data. (D) Global difference between simulated and clinically measured data. Similar curve fittings to
(B) are done for other situations (from 1 to 10 times the measured extrasynaptic levels). Because the in vivo serotonergic firing frequency is
around 1 Hz, we took great care to fit the low end of the frequency datapoints.
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such as blood-brain barrier transport and free fraction and
reflects the actual true concentration of the drug.
With the radiotracer altanserin, a 65% block was
observed after 6 month treatment with 300 mg quetiapine
[56]. The affinity of altanserin and quetiapine for 5-HT2A
receptor was described with a Kivalue of 0.3 nM (Tan et
al., 1999) and 264 nM, respectively. Using setoperone as a
5-HT2A receptor tracer, 80%, 90% and 10% displacement
was observed with 600 mg chlorpromazine, 200 mg cloza-
pine and 10 mg amisulpride, respectively [57], while a
dose-range of 10 to 100 mg loxapine resulted in occu-
pancy between 27 and 100% [58]. Similarly, 10 mg amoxa-
pine displaced setoperone for over 90% [59].
For each of the conditions mentioned above, we then
simulated the displacement of the tracers setoperone or
altanserin by the appropriate functional brain concentra-
tion of the antipsychotic, given its known affinity for the
human 5-HT2A receptor. Because the amount of tracer
displacement results from a complex interaction between
tracer, drug and serotonin, it will depend upon the abso-
lute level of free 5-HT. We further assume that these
values for the human 5-HT synapse can be extrapolated
to normal healthy subjects or Alzheimer patients, as schi-
zophrenia is mostly associated with a dopamine, but not
a serotonergic dysfunction [60,61].
Using the functional concentrations of the antipsycho-
tics derived from the raclopride displacement studies, we
then simulated the displacement of 5-HT2A receptor tracer
for the seven clinical cases for each of the ratios of intrasy-
naptic versus extrasynaptic 5-HT levels and compared the
outcomes with the clinically reported data.
The calibration suggests that a ratio of intra- over extra-
synaptic free 5-HT of 2 times gives the best correlation
with the human imaging data (Figure 4C). We therefore
used this value for all subsequent experiments with seroto-
nin modulators.
Target engagement of cholinergic and serotonergic drugs
in AD clinical trials
Cholinergic drugs
Acetylcholinesterase inhibitors (AChE-I), such as done-
pezil, galantamine and rivastigmine have been tested
extensively in the clinical AD trials. Imaging studies with
acetylcholinesterase specific radiotracer 11C-PMP have
reported inhibition levels of 40% for 10 mg donepezil and
12 mg rivastigmine and 35% for 16 mg galantamine
[62-64] in the brain in Alzheimer’s disease at clinically
relevant doses.
Assuming a mass equation relationship, that is Ki = D
(1 − l)/l, where D is dose and l is inhibition level, we
determined the clinical Kidoses for AChE-I from the
above reported inhibition levels as 15 mg for donepezil,
30 mg for galantamine and 18 mg for rivastigmine.
Blocking the acetylcholinesterase enzyme to a level l,
increases the half-life of free ACh in the synaptic cleft
to τ0/(1 − l), where the basal half-life τ0 is 5 ms.
These changes in half-life of ACh were then applied in
our cholinergic receptor competition model to determine
the subsequent postsynaptic receptor M1 mACh-R, a7
nACh-R and a4b2 nACh-R activation, with the presynaptic
cholinergic receptor being of the M2 muscarinic type for
each of the doses of the AChE-I. We further assumed lin-
ear pharmacokinetics relative to the dose of the AChE-I.
Serotonergic drugs
The 5-HT6 antagonist SB742457 is currently in Phase II
for Alzheimer’s disease and clinical results as a stand-
alone medication have been reported [6,7] for 5, 15 and 35
mg. Using target engagement studies [65], these doses
have been shown to displace 84, 94 and 97% of the radio-
tracer GSK215083. We determined the functional concen-
tration of SB742457 corresponding to these tracer
displacement values and subsequently the resulting postsy-
naptic 5-HT6-R activation level for the 3 doses of
SB742457 using the calibrated humanized 5-HT synapse.
This resulted in postsynaptic 5-HT6-R activation levels of
40.6%, 12.9%, 5.1% and 3.1% for placebo, 5, 15 and 35 mg
of SB742457 respectively.
Results
We extended a biophysical model of cortical circuitry
that was calibrated with primate electrophysiology data
[11]. Although this model is very detailed and complete,
it has been calibrated using only single-unit electrophy-
siology data in preclinical animal models. In addition,
the absence of neuromodulatory drug targets and clini-
cal calibration make the model less useful for supporting
research and development programs. Our extensions of
the model are to (1) implement the physiology of a
number of neuromodulatory receptors based upon pre-
clinical physiology, (2) increase the size of the network
to 80 pyramidal cells and 40 inhibitory interneurons to
accommodate higher resolution for the AD pathology,
(3) reduce the relative fraction of inhibitory synapses
according to recent neuroanatomical data, (4) imple-
ment the pathology of Alzheimer’s disease based upon
human pathology data and (5) calibrate the remaining
biological coupling model parameters using the correla-
tion between the effects of therapeutic interventions and
genotypes in the model and the reported ADAS-Cog
clinical effects. The model includes the physiology of
the dopamine D1, D2 and D4 receptors, the serotonin 5-
HT1A, 5-HT2A, 5-HT3, 5-HT4 and 5-HT6 receptors, the
adrenergic a2A receptor and cholinergic M1, M2
mACh-R, and a7 and a4b2 nACh-R, whereas the phar-
macology of 5-HT6 antagonism includes increases of
glutamate and acetylcholine in the cortex.
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Calibration neuronal and synapse loss in the Alzheimer’s
disease model network
Prodromal AD stage
This section is devoted the calibration of synapse and
neuronal loss occurring during amnestic MCI, a prodro-
mal stage leading up to the clinical diagnosis of AD.
This transition point is characterized by a precipitous
drop in cognitive performance. We therefore determined
the minimal loss of neurons and synapses where the
performance of the network starts to break down.
In a systematic parameter space of synapse and neuronal
loss between 0 and 5% we determined that neuronal loss
of 3-4% and beyond leads to substantial decrease in work-
ing memory performance. Be-cause of the finite nature of
the network (80 pyramidal cells), real differences are seen
at 2, 4 and 5% loss. We also introduced a ‘cholinergic
compensatory’ mechanism which raised the levels of free
ACh in the cortex by 10% and consequently increased
activation of M1, M2 muscarinic receptors and of a7 and
a4b2 nicotinic receptors. Based upon these simulations, we
determine the threshold for AD to be at 5% neuronal cell
loss (Figure 5).
Progression of Alzheimer pathology
Once we had determined the minimal deletion of synapses
and neurons that corresponds to the transition between
MCI and AD, we then proceeded to calibrate the remain-
der of the free parameters that describe the progression
over time, the placebo effect and the coupling of the var-
ious pharmacological interventions.
We first applied a DOE approach to find the optimum
in the 7-dimensional parameter space, using a 2n (14)
runs matrix to achieve a first identification of the drivers
for this optimization. Basically for each of the 14 different
combinations of minimum and maximum values we cal-
culated the correlation coefficient between model outcome
for the 28 different clinical conditions and their reported
clinical results and the corresponding slope. The Pareto
plots suggested that the major drivers for the optimization
of the correlation were %-synapse loss and %-neuronal cell
loss. After three iterations and 17 further optimization
steps we arrived at the correlation between model out-
come and clinical ADAS-Cog scales in Figure 6.
Table 4 shows the optimal set of parameters as deter-
mined by the previous experiments. When using a linear
fit, the correlation is r2 = 0.73 with these parameters.
When fitting with a second degree polynomial, the corre-
lation increases to r2 = 0.87 (data not shown).
When studying the correlation between clinical out-
comes and model outcomes at different time points
(Figure 7), the calibration results in (1) a correlation coeffi-
cient of r2 = 0.58, a slope of -1.4 ADAS-Cog points/WM
sec, and p = 0.02 for the 8 points at 12 weeks; (2) a corre-
lation coefficient of r2 = 0.47, a slope of -2.7 ADAS-Cog
points/WM sec, and P = 0.013 for the 11 points at
26 weeks; (3) a correlation coefficient of r2 = 0.52, a slope
of -3.7 ADAS-Cog points/WM sec, and P = 0.035 for the
8 points at 52 weeks. This suggests that the model is able
to capture the individual differences of each therapeutic
intervention and the global correlation is not driven pro-
minently by the differences between outcomes at 12 and
78 weeks. The data also suggest that the slope of ADAS-
Cog points per working memory second increases from
-1.45 at early time points (corresponding to mild AD) to
-3.72 at later time points (corresponding to moderate AD).
Figure 5 Working memory loss. Slope of working memory loss (defined as the decrease of working memory span per percent of
deleted synapses) with increasing fractions of neuronal cell loss. It is clear that from 4% the decrease in performance accelerates substantially.
As expected, having a greater cholinergic compensation tends to attenuate the decrease in working memory performance.
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Interestingly, the optimal parameter relating M1 recep-
tor activation change to degree of AChE inhibition corre-
sponds to the increase in postsynaptic M1 receptor due
to the increased ACh half-life as determined. For 8 mg
galantamine this resulted in 9.1% increase in M1 receptor
activation. This suggests that the network automatically
converges towards a biologically reasonable value for this
particular free parameter.
Response surface analysis
In this subsection we studied the sensitivity of the calibra-
tion parameters, i.e. how do small changes in parameters
affect the value for the slope between changes in working
memory span (sec) and corresponding changes in ADAS-
Cog points.
A sensitivity analysis was performed by keeping all but
one parameter constant and testing the parameter region
around the value identified in the full-factorial approach.
We then determined how much the location of the opti-
mum is dependent on the value of a particular parameter.
Ideally one would not accept substantial changes in the
correlation outcome with small changes in a specific
parameter.
Figure 6 Figure 6 Global correlation between Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) outcomes and
model predictions. Global linear correlation between reported ADAS-Cog outcomes from 28 different therapeutic interventions and their
corresponding working memory effects in the computer model of Alzheimer’s disease (P <0.0001). Because ADAS-Cog readouts monitor errors,
positive values are associated with shorter working memory spans and worse performance.
Table 4 Free parameters
Name Description Biological Range Optimal
Value
Reference
Slope %Syn Slope of fraction of synapses disappearing/week Max 0.075%/week, on top of neuronal
loss
0.004 [94]
Slope %Neuron Slope of neurons eliminated/week Max 0.5%/week, leads to 50% neuron
loss in 100 weeks
0.025 [78]
ACh deficit Size of the cholinergic NBasalis deficit Range 5-50% loss 0.175 [41,95]
5-HT6 effect Relation between 5-HT6 inhibition and
free DA, ACH and
NE increase
Maximum 0.20 0.025 [33]
DA increase in 12 wk
placebo
DA surge from reward circuit that simulates
placebo effect
Maximal 20% (tracer displacement in
volunteers)
0.075 [42,96]
Rel a7 vs. a4b2 nACh-
R effect
Relative effect of a7 over a4b2 nACh-R
mediated effects
Depends upon dose and nature of
enhancement Range 0.4-2.0
2 [97]
AChE-I effect on M1
receptor activation
AChE-I increases M1 mACh-R activation level to
make pyramidal cells more excitable
Maximal change in membrane resting




List of 7 free parameters that were calibrated using the relation between clinical outcomes and working model outcomes. We report also the neurophysiological
implementation and the biologically realistic boundaries, together with the value determined for the optimal correlation. With these 7 parameters on a database
of 28 individual data points we achieve a correlation of r2 = 0.73.
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Figure 7 Weekly correlation between Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) outcomes and model
predictions. (A) Correlation between changes in reported ADAS-Cog outcomes from 7 different therapeutic interventions at week 12 and their
corresponding working memory effects in the computer model of Alzheimer’s disease (P = 0.038). For the time points, the data show that even
for individual time points there is a good correlation between clinical outcome and corresponding computer model outcome. (B) Correlation
between reported ADAS-Cog outcomes from 12 different therapeutic interventions at week 26 and their corresponding working memory effects
in the computer model of Alzheimer’s disease (P = 0.042). (C) Correlation between reported ADAS-Cog outcomes from eight different
therapeutic interventions at week 52 and their corresponding working memory effects in the computer model of Alzheimer’s disease (P = 0.031).
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Studies of changing the ACh deficit coupling in the range
0.075 to 0.4 revealed only a 10% decrease in the correlation
value around the optimum point (0.15). In addition the
slope of working memory span change in seconds to
ADAS-Cog clinical points change similarly, between -2 and
-2.7 ADAS-Cog points/sec.
Similarly, the sensitivity of the slope outcome with
regard to the 5-HT6 coupling effects showed even less
sensitivity. Over a range from 0.005 to 0.04, around the
optimal value of 0.025, the correlation value decreases
less than 10%.
Changing the range of synapse loss slope (percent
synapses lost per week pathology), between 0.028 and
0.043 resulted in a monotonic decrease in working mem-
ory, as expected, especially at the earlier stages (12 and 26
weeks). The value for the correlation varies within 14%
and for the slope within 18%. Although somewhat greater
than the values for ACh deficit and 5-HT6 effects, this sug-
gests a limited sensitivity of the optimal parameter choice
to the parameter of synapse loss.
As expected, neuronal loss pathology has the biggest
effect on the network performance. This is the most sensi-
tive parameter being fit. However, the value we chose
(0.25%) has the highest correlation. For values between 0.2
and 0.5; the correlation ranged from a maximum of 0.73
to 0.39 and the slope of the correlation function ranged
from -1.5 to -2.7.
The effect of APOE genotype on the network
performance in AD
The most important risk factor for AD is the ApoE4 geno-
type [66]. While the exact molecular sequence is currently
unknown, many data suggest a decreased synapse density
[47] and a lower cholinergic tone [48] to be associated
with the ApoE4 genotype. We therefore implemented
these effects in the network model for both the MCI and
the AD case.
Simulation results in Figure 8 show that the effect of
synapse loss is more pronounced in the earlier stages of
the pathology than in the later stages. As expected, there
is a dose-dependent decrease of working memory perfor-
mance with increasing additional loss of synapses.
An additional 3 or 5% loss of synapses on top of the
already lower synapse density as part of the AD pathology
has the biggest effect at the early stages, that is, when the
number of lost synapses is relatively lower. For instance
going from a 3% synapse loss to a 6% synapse loss with 3%
neurons lost (MCI case) has a much larger effect than
going from 7 to 10% synapse loss with 23% neurons lost
(the 52 week case). Using the calibration data, a 10-15%
Figure 8 Model validation with ApoE4 genotype in the Alzheimer’s disease (AD) cortical network. Effect of additional synapse loss and
cholinergic tone decrease as part of the ApoE4 genotype in the AD cortical network on relative changes in network working memory span. We
assume a 3% loss for 1 ApoE4 allele and a 5% loss for two ApoE4 alleles. The datasuggest that the biggest negative effect of synapse loss is
observed in the early stages.
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decrease in network performance at earlier AD stages cor-
responds to a difference of 1-1.5 points on the ADAS-Cog
scale. This result is qualitatively in line with clinical data
suggesting that APOE has its biggest effect on the age of
onset for AD [67], that is, in the very early prodromal
stages of AD but much less on the progression of the dis-
ease once diagnosed [68].
For the cholinergic compensation in the MCI state, we
assumed a 10% increase in Ach levels and calculated the
corresponding change in postsynaptic mAChR and
nAChR. Such a value is in line with the compensatory dif-
ferences in ChAT staining observed in the brain of MCI
patients [69]. The cholinergic deficit in the AD pathology
state was fixed at 30% decrease and was unchanged over
the progression of the disease. On top of this deficit,
APOE4/4 carriers had an additional Ach decrease that was
calculated with the receptor competition model to satisfy
the imaging studies of the M2 specific radiotracer [48].
Figure 8 shows the effect of the cholinergic compensation
to attenuate the deficit slope: from 0.06 to 0.01 for a neu-
ronal cell loss of 2%, from 0.28 to 0.23 at 4% and from
0.40 to 0.30 at 5% neuronal cell loss.
The effect of memantine in different AD pathology
conditions
Memantine is a weak NMDA antagonist that is approved
for moderate to severe Alzheimer’s disease [70]. Interest-
ingly the drug has been shown to decrease cognitive per-
formance in healthy volunteers [71], improve cognitive
function in mild-to-moderate AD patients [72], but has
the greatest effect in later moderate to severe AD stages
[8,73], where it is approved. We explore here the glutama-
tergic component of memantine. Recent studies suggest
that memantine under physiological concentrations of
Mg2+ inhibits the NMDA receptor NR2C/D subunits
more than the NR2A/2B subunits [74]. Based upon the
observation that the NR2C/2D subunits are preferentially
located on inhibitory interneurons [75] in rats, we
explored whether a greater inhibition of the NMDA recep-
tor on interneurons would result in a differential effect of
memantine at later stages of the AD pathology.
Data suggest that functional memantine concentration
in the human brain is relatively small; together with the
intrinsic pharmacology as a weak and uncompetitive
inhibitor at the NMDA receptor [76], suggesting a small
decrease in NMDA functionality.
Figure 9A shows the effect of a decrease of 0.5% in the
excitatory NMDA receptor and 1% in the inhibitory
NMDA receptor on the network performance. These
simulation results suggest that memantine decreases per-
formance in normal individuals, but tends to improve the
network performance better at later stages of the AD
pathology, when more excitatory neurons are eliminated.
In contrast, a hypothetical compound that blocks both
NMDA subtypes to the same degree, leading to the same
level of inhibition at both excitatory and inhibitory gluta-
matergic synapses improves the network performance at
all pathology stages. This differential effect of memantine,
especially the decrease at the earlier stages was only
observed at relatively low values of memantine-induced
NMDA conductance effects (that is,<2%).
The calibrations on the ADAS-Cog suggested a base-
line of 5% synapse loss and 5% neuronal cell loss at
time 0 of the clinical trial; therefore an MCI pathology
is defined as a loss of 3% for synapses and a loss of 4%
for neuronal cells. This leads automatically to the results
Figure 9 Effect of memantine pharmacology. (A) Effect of memantine pharmacology as represented by a 0.5% decrease in N-Methyl-D-
aspartic acid (NMDA) conductance on excitatory-excitatory and 1% decrease of NMDA conductance on excitatory-inhibitory glutamate synapse
on cortical AD network outcome. Memantine leads to a deterioration in the very early stage MCI (mild cognitive impairment) that further turns
into a stronger positive effect as the pathology (i.e. loss of synapses and neurons) advances. (B) Sensitivity analysis of the difference between
memantine and placebo effect for different values of amount of synapse and neuronal cell loss. The MCI state is defined as 3% synapse loss and
4% neuronal cell loss (indicated by ★ on the figure). A negative outcome corresponds to a decrease in performance after memantine. The effect
of memantine is conserved over a range of synapse loss (1-5%) and neuronal cell loss (4-5%).
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observed in Figure 8 that suggest a worsening effect of
this pharmacology in earlier stages of the pathology
while providing a beneficial effect at later stages. We
subsequently did a sensitivity analysis around the differ-
ential effect of memantine versus placebo in different
pathological states of MCI (Figure 9B); suggesting that
the decrease in working memory readout is relatively
independent of the level of synapses deleted or the frac-
tion of neurons deleted (4 or 5%). The lack of differen-
tiation for a neuronal cell loss of 2% probably reflects
the saturation of network readout.
Discussion
This report describes the implementation and calibration
of a computer-based mechanistic and biophysically realis-
tic neuronal network model for working memory with
Alzheimer’s pathology. Although such network models
have been developed in the past [11,77], they have not
been made actionable for the modeling of drug effects and
pharmaceutical research and development. A position
paper [9] suggests that an upscaling of modeling from
intracellular and molecular modeling to network and cir-
cuit modeling is essential for computational disease mod-
eling. We believe that our combination of the receptor
competition model, which describes the effect of drugs on
the receptor activation level, with cortical network model-
ing of biophysically realistic neurons might be a first step
in that direction.
A major difference to previous pharmacological research
using modeling and simulation is the implementation of
the proper target engagement by the drugs in the clinical
situation. This is necessary in order to determine the
receptor or target activity level at the appropriate clinical
drug concentration. We first calibrated the receptor com-
petition model using preclinical fast cyclic voltammetry
data on serotonin in rodents [51]. As these experimental
results likely reflect extrasynaptic neurotransmitter levels,
we then constrained the relation between intra- and extra-
synaptic values using PET displacement studies in humans
using appropriate 5-HT and DA tracers. In order to get
functional antipsychotic drug concentrations in the model,
we simulated the tracer displacement experiment in
human patients using this calibrated receptor competition
model, which eliminates basically all issues about brain
penetration. Finally we determined the effect of these
drugs on the average activation level of the different recep-
tor or target subtypes which then were entered in the net-
work model.
Another major improvement to make this platform
actionable for drug discovery and development is para-
meter calibration using correlation between model out-
come and clinical results from retrospective data. Ideally
all values for the coupling between neuromodulatory
receptor activation and downstream effects on ion channel
conductances should be derived from actual molecular bio-
logical measurements; however the only available data are
from rodents or primates. Traditionally modeling studies
calibrate the parameter set using the similarity with elec-
trophysiological outputs from rodents and non-human
primates. Our starting point was a cortical model [11] that
was been calibrated using single-unit recordings in pri-
mates. As the human neurophysiology might be substan-
tially different from the rodent or primate neurophysiology
and to make it more translational, we used the correlation
between model outcome and actual clinical test results on
a cognitive test to determine the calibration parameters.
The results with the retrospective clinical data suggest
that the calibration slope of ADAS-Cog points is about
-2.8 points/sec of working memory and that this slope is
steeper at longer time points (or more severe pathol-
ogy), that is, a slope of -3.7 ADAS-Cog points/sec work-
ing memory at 52 weeks and a slope of -1.5 ADAS-Cog
points/sec working memory at 12 weeks. It is unclear
whether this corresponds to a ‘cognitive’ inflection point
as has been suggested [78].
The progression of the neuronal cell loss in placebo
conditions is about 0.35%/week, which corresponds to
18% per year or 5.2 years for a total decrease. This is in
line with estimates for the time it takes for intraneuro-
nal paired helical fillaments to become a ghost tangle:
about 3.4 years in the hippocampus CA1 regions and
5.4 years in the subiculum [79].
In this model, we assumed that the major effect of the
cholinomimetics was through their effect on acetylcholi-
nesterase. Rivastigmine is the only drug that also blocks
the enzyme butyrylcholinesterase (BuChE). However, the
contribution of BuChE to the degradation of ACh in the
cortex is relatively unknown. The major effect of rivas-
tigmine, a combination of its activity against BUChE
and the pseudo-irreversible cholinesterase inhibition, is
the differential up-regulation of AChE and BuChE in
the cerebral spinal fluid of patients after chronic treat-
ment [80]. Rivastigmine is the only drug that reduces
both activity and protein levels in the cerebral spinal
fluid. Given the complex and undocumented nature of
the relation between cerebral spinal fluid levels and
actual brain activity levels of AChE and BuChE, we did
not include the up- or down-regulation of the cholines-
terases over time for this numerical model.
The cholinergic pathology is implemented as a loss of
neuronal fibers with the assumption that the remaining
cholinergic innervation function normally, that is, with the
same presynaptic kinetics. This resulted only in a decrease
of the amount of ACh released that had further impacted
the activation levels of the postsynaptic muscarinic and
nicotinic receptors.
We further assumed that the 5-HT dynamics were
unchanged over the course of the disease pathology.
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There is indeed evidence that the noradrenerge system
in the locus coeruleus [81], but not the dorsal raphe
5-HT is affected in AD pathology [82]. If new data
become available, for instance using specific radiotra-
cers, this could easily be introduced in the mechanistic
disease platform.
An important test of any numerical model is the repro-
duction of clinical results not used for calibration. The
observation that the model qualitatively reproduces both
the observed clinical effects of APOE genotype and mem-
antine likely increases the confidence in the model’s
predictions.
Selective synaptic loss affects the model outcome much
more in earlier stages of the pathology in the network,
likely because this is a proportional bigger decline in func-
tional synapse loss than at later stages. Assuming that this
synapse loss is a major hallmark of the ApoE4 genotype
[47], this is qualitatively more in line with clinical data
[67,68] that suggest that the APOE genotype has its big-
gest effect in determining the age of onset.
Similarly, the model qualitatively recapitulates the differ-
ential clinical beneficial effects of memantine, a weak
NMDA antagonist, as a function of the pathology [8,71].
This is not a trivial result because reducing NMDA activ-
ity in preclinical models has been consistently associated
with a decline in cognitive performance. Analyzing the
model results suggests that a relatively greater inhibition
by memantine of the NMDA receptor synapsing upon
inhibitory interneurons by its virtue of its preferential
block the NMDA receptor NR2C subunit can explain this
apparent contradiction.
Interestingly, in our computational neuronal network
model without AD pathology, the effect of blocking inhibi-
tory NMDA receptor has always more impact than redu-
cing NMDA receptor on excitatory synapses to the same
degree, leading to an enhanced excitation or working
memory span. This makes it even more difficult to detect
a global inhibitory effect when blocking the inhibitory
NMDA receptor more than the excitatory NMDA recep-
tor as in the case of memantine. Only the combination of
a specific pathology and the specific memantine differen-
tial effect on both types of NMDA receptor leads to the
observed decreased working memory span. Therefore it is
unclear if the absolute range of values for the memantine
induced effects would translate into the clinical situation,
because they might be related to the specifics of the com-
puter model. Nevertheless, it is of interest that this model
provides an explanation of the differential effect of mem-
antine in diverse pathology states.
Memantine might have other pharmacological targets
beyond the NMDA receptor [83] and it has been
argued, based upon rodent animal studies, that the clini-
cal effect of memantine is unlikely to be driven by its gluta-
matergic action [84]. When focusing on the glutamatergic
component in this quantitative systems pharmacology
model, the data indeed suggest that the clinical observation
of differential effects in early stage versus more severe
AD can only be reproduced when the effect is limited to a
very small range of NMDA receptor inhibition. As this
model has been extensively based upon primate electro-
physiology data this could be a result of the consequences
of differential inhibitory tone in primates versus rodents. It
has indeed been shown that primate inhibitory tone is
more pronounced than rodent inhibitory tone as a conse-
quence of faster firing dynamics and higher interneuron
density [85]. In short, this is an example where this type of
quantitative systems pharmacology can help elucidate
important clinical questions and translational divergences
between rodent and humans.
A limitation of the model is the relatively low number
of neurons (120) used in this simulation paradigm.
Other approaches such as the Blue Brain project use
massive parallel computing to simulate a neocortical
column consisting of 10,000 3D digitizations of real
neurons and that are populated with model ion channels
constrained by the genetic makeup of over 200 different
types of neurons [86]. The small number of neurons in
the network might seem to be a concern; however
recent studies in primates suggest that the behavior in a
visual working memory paradigm can be described by
the activity of only a few hundred cells [87]. In addition,
the validation results suggest that a comparatively small
network model can reveal drug mechanisms of action
and guide drug development.
Another limitation is the fact that the model uses a
very simplified representation of the pyramidal neuron
and the inhibitory interneuron. While the small number
of neuronal compartments might speed up the calcula-
tion, it is by far not a complete representation of a
human neuronal cell. In addition, the model uses only
one type of interneuron, the fast-spiking basket inter-
neuron, while it is known that the human cortex has
many different types [88]. For other types of physiological
readouts, such as the simulations of brain oscillations,
there may be a need for multiple different types of inter-
neurons. However, even such a simplified network is able
to qualitatively represent the emergent property of a
stable activity pattern that mimics a working memory
property, as evidenced by the similarity of the model
outcome with electrophysiology readings in primates
performing such a task [11]. This is not unlike the obser-
vation that many different parameter sets might lead to
identical emergent properties [89].
Although working memory decline is certainly present
in the disease and seems to be sensitive to cholinomimetic
treatment, only a small part of the ADAS-Cog is really
dependent on working memory [90]. Indeed, a small study
with 5mg donepezil in both elderly controls and mild AD
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patients documented a significant improvement in Groton
maze learning [91], a task involving spatial working mem-
ory and error monitoring. AD patients seem to perform
better in complex working memory tasks of high value,
but not low-value items [92]. Another way to interpret the
results from this network model is to consider the model
as measuring the stability of a memory representation,
irrespective of the nature of the cognitive task.
Conclusions
The results presented here demonstrate that quantitative
systems pharmacology approach can be complementary
to traditional animal models to predict the efficacy of
pharmacological treatments for patient subtypes. This
type of systems level computational modeling has the
potential to assess potential off-target effects, the conse-
quences of pharmacologically active human metabolites,
the effect of comedications, and the impact of well
described genotypes. Our particular implementation of
quantitative systems pharmacology can generally aid
drug research and development in the central nervous
system as it uses human-specific properties of candidate
drugs, such as more realistic drug exposure, specific
pharmacology against the human receptors, the pharma-
cological effect of unique human metabolites and func-
tional genotypes unique to the human situation with an
effect on cognitive outcome [93]. It recapitulates part of
the neurophysiology and neuropathology of Alzheimer’s
diseases, and although incomplete in physiological
details, can help in assessing the effect of human-specific
properties of clinical candidates and improve the clinical
success rate.
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